OBJECTIVES

To create a pilot urologic malignancy registry using demographic and clinical data of a cohort of patients newly diagnosed to have urologic malignancies in the year 2021.

METHODS

This was a prospective cohort study conducted in four study sites: National Kidney and Transplant Institute, East Avenue Medical Center, UP-Philippine General Hospital and Batangas Medical Center

RESULTS

A total of 243 patients with newly diagnosed urologic cancers were enrolled. The median age was 61 years, with a wide range of 1 to 87 years. Most of the patients (81.47%) were male, while there were 45 females (18.52%) who had either urinary bladder, kidney or upper urothelial cancer. The most common type of malignancy was prostate cancer (34.57%), followed by kidney cancer (30.04%) and urinary bladder cancer (24.69%), consistent with the currently observed worldwide incidence. There were also 3 patients (1.23%) noted with multiple primaries. More than half of the patients (63.37%) received surgery as active treatment. After the two-year follow-up period, thirteen patients (5.35%) developed progressive disease, and 14 patients (5.76%) died.

CONCLUSION

This urologic cancer registry represents the first multi-center, investigator-initiated epidemiologic study of its kind in the Philippines. As a proof-of-concept (POC) project, it demonstrates the feasibility of establishing a national database capturing baseline data on the country’s most common urologic malignancies.

Cohort Studies ; Multiple Chronic Conditions ; Prostatic Neoplasms ; General Surgery ; Epidemiology

INTRODUCTION

Despite universal agreement on the application of antimicrobial prophylaxis, the optimum administration period of antibiotics for percutaneous nephrolithotomy (PCNL) remains controversial and the risk for antimicrobial resistance due to prolonged antibiotic use as well as financial burden that may prove to be challenging for both the patient and the physician. This study therefore aims to determine the safety and effectiveness of a single dose antibiotic prophylaxis in patients undergoing PCNL.

METHODS

A randomized controlled trial was conducted in PCNL patients between 2021-2023. The patients were randomly assigned to three groups: single dose prophylaxis 30 minutes before surgery arm (Group A), 30 minutes before and 12 hours after surgery arm (Group B), and continued antibiotics until removal of nephrostomy tube arm (Group C), respectively.

RESULTS

A total of 81 patients were included (Group A=27, Group B=28, and Group C=26). The rate of comorbidities did not differ significantly in the three groups: HTN (p=0.166), DM (p=0.121), and Others (p=0.405). The presence of hydronephrosis was seen in 70.4% of patients. About half had solitary stone type (54.3%) and had left area affected (51.8%). Also, 14.8% had history of UTI. The patient groups did not differ in clinical and operative characteristics (all p > 0.05) except in history of previous stone surgeries. Significantly more patients had previous history of stone surgeries in Group A (37.0%) than in Group B (3.6%) and Group C (15.4%) (p=0.006). The following proportion of no growth in preoperative urine culture was observed: Group A (92.6%), Group B (89.3%), and Group C (80.8%) (p=0.174). The estimated blood loss was significantly lower in Group A (130.7ml) than in Group B (235.7ml) and Group C (261.5ml) (p=0.032). Significantly less patients in Group A were free from stone (74.1%) compared to Group B (92.9%) and Group C (96.2%) (p=0.030). After surgery, only two patients (2.5%) had criteria consistent with SIRS and both belonged in Group C. No significant difference in incidence of SIRS was observed among the three groups (p=0.067).

CONCLUSION

Single dose antibiotic prophylaxis for the prevention of post-operative bacterial infection in patients undergoing PCNL is as effective as multiple dose antibiotic prophylaxis. Consistent with existing guidelines on PCNL, single dose antibiotic prophylaxis is highly recommended as it is more cost-effective and may lower the risk for antibiotic resistance in the future. More RCTs with larger sample size which can determine the effectiveness of single dose antibiotic prophylaxis in patients at high-risk for post-operative PCNL infections are recommended.

Systemic Inflammatory Response Syndrome

AIM

This study aims to evaluate the clinical utility of Power Doppler Ultrasonography (PDUS) in the detection of prostate cancer and determine its predictive ability compared to digital rectal examination, serum PSA levels and gray-scale transrectal ultrasonography, using biopsy as the reference standard.

MATERIALS AND METHODS

This is a prospective cross-sectional study of 49 consecutive patients, who underwent prostate needle biopsies at the National Kidney and Transplant Institute. All patients were seen at the out-patient department and suspected of having prostate cancer because of abnormally high serum PSA levels (>4 ng/ml) and/or abnormal digital rectal examination. Patients previously diagnosed with prostate cancer were excluded in the study. All patients underwent gray-scale TRUS before power Doppler imaging of the prostate using the Siemens Sonoline Elegra high resolution digital ultrasound with a 6.5 MHz endocavitary probe. After power Doppler imaging, a systematic 1 2-core and lesion-directed TRUS-guided biopsy of the prostate was performed.

RESULTS

A total of 49 patients (mean age 64.45, SD 7.53, range 41-79) were included in this study. Prostate needle biopsy confirmed 15 (30.6%) to have prostate cancer. Of the 15 patients diagnosed with prostate cancer, 5 (33.3%) had an abnormal DRE, 10 (66.7%) had abnormal TRUS findings, 3 (20%) had positive power Doppler flow. PDU had a positive predictive value of 60% and a specificity of 94.1 %. Multivariate logistic regression analysis with the odds ratio computed at 95% C.l. showed that the addition of PDUS to the standard procedure for prostate cancer detection using DRE, serum PSA, and TRUS resulted in a higher sensitivity and better overall predictive performance.

CONCLUSION

The overall prostate cancer detection rate was 30.6% with a sensitivity of 66.7% for gray-scale TRUS and 20% for power Doppler ultrasonography. PDUS increased the predictive value and specificity of Gray-scale TRUS. The addition of PDUS to the standard procedure for prostate cancer detection using DRE, serum PSA, and TRUS resulted in a higher sensitivity and better overall predictive performance.

Human ; Prostatic Neoplasms